Buy Boletraaz : Everolimus 5 mg Tablets Online

Description

Description:

Boletraaz is a medication manufactured by Alkem Laboratories Ltd., containing the active ingredient Everolimus. Each tablet typically contains 5mg of Everolimus. Everolimus belongs to a class of medications called mammalian target of rapamycin (mTOR) inhibitors. It is used for the treatment of various types of cancers and certain non-cancerous conditions.

Indications:

Boletraaz is indicated for the treatment of the following conditions:

1. Cancer: Everolimus is used in combination with other medications for the treatment of certain types of cancers, including advanced renal cell carcinoma (kidney cancer), hormone receptor-positive advanced breast cancer, neuroendocrine tumors of pancreatic origin, and subependymal giant cell astrocytoma (a brain tumor associated with tuberous sclerosis complex).
2. Non-Cancerous Conditions: Everolimus is also used to prevent organ rejection in certain transplant patients (e.g., kidney or liver transplant) and to treat certain non-cancerous conditions such as tuberous sclerosis complex (TSC) and lymphangioleiomyomatosis (LAM).

How It Works:

Everolimus works by inhibiting the activity of a protein called mammalian target of rapamycin (mTOR), which plays a role in cell growth, proliferation, and survival. By blocking the mTOR pathway, Everolimus helps to slow down or stop the growth and spread of cancer cells and suppresses the immune system to prevent organ rejection in transplant patients.

Dosage and Administration:

The dosage of Boletraaz depends on the patient’s medical condition, response to treatment, and other factors such as body weight and kidney function. It is usually taken orally once daily, with or without food, as directed by a healthcare professional. The tablets should be swallowed whole with a glass of water and should not be crushed, chewed, or broken.

Possible Side Effects:

Common side effects of Boletraaz may include:

1. Fatigue: Feeling tired or weak is a common side effect reported by patients taking Everolimus.
2. Nausea and Vomiting: Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and loss of appetite may occur.
3. Mouth Sores: Some patients may develop mouth sores or ulcers during treatment with Everolimus.
4. Infections: Everolimus can increase the risk of infections, including respiratory infections, urinary tract infections, and skin infections.
5. Skin Rash: A rash or skin irritation may occur, which can be mild to moderate in severity.
6. Changes in Blood Counts: Everolimus can cause changes in blood cell counts, including low white blood cell count (neutropenia), low red blood cell count (anemia), and low platelet count (thrombocytopenia).

Warnings and Precautions:

1. Immune Suppression: Everolimus can weaken the immune system, increasing the risk of infections and certain types of cancer. Patients should avoid close contact with individuals who have contagious illnesses and report any signs of infection to their healthcare provider.
2. Kidney Function: Everolimus can affect kidney function, and kidney function should be monitored regularly during treatment.
3. Liver Function: Liver function tests should be performed before starting treatment with Everolimus and monitored regularly during treatment, as it can affect liver function.
4. Pregnancy and Breastfeeding: Everolimus can cause fetal harm and should not be used during pregnancy. Women of childbearing age should use effective contraception during treatment and for a period after discontinuation of therapy. It is not known whether Everolimus passes into breast milk, so breastfeeding is not recommended during treatment.

Boletraaz by Alkem Laboratories Ltd. is a prescription medication used for the treatment of various types of cancers, transplant rejection prevention, and certain non-cancerous conditions. Patients should follow their healthcare provider’s instructions regarding dosage, administration, and monitoring for adverse effects. Any concerns or potential side effects should be discussed with a healthcare professional.